Q32 Narrows Loss, Funds Bempikibart Through Phase 3 Readout
The biotechnology company ended June with $106.3 million in cash before completing a roughly $200 million public offering.
Q32 Bio (QTTB), a clinical-stage biotechnology company, reported a narrower second-quarter loss as reduced spending on a divested program offset higher administrative and bempikibart-related costs.
The July offering extended Q32’s projected cash runway through topline Phase 3 results from its planned registration-directed bempikibart program. The proceeds were excluded from the June 30 cash balance, which had increased from $48.3 million at year-end, while venture debt declined to zero from $9.7 million.
The net loss narrowed to $8.9 million, or $0.44 a share, from $9.5 million, or $0.78 a share, a year earlier. Q32 did not report revenue in the supplied results.
Research-and-development expense fell to $4.3 million from $5.2 million, reflecting lower ADX-097 spending after the program’s November 2025 sale. Higher manufacturing and nonclinical costs for bempikibart partly offset that decline, while general-and-administrative expense rose to $4.9 million from $4.0 million, primarily because of increased stock-based compensation and other expenses.
The cost shift was more pronounced over the first half. Operating expenses declined to $16.8 million from $21.4 million as R&D fell to $7.5 million from $12.3 million, outweighing a modest increase in G&A. The first-half net loss narrowed to $16.6 million, or $0.96 a share, from $20.5 million, or $1.68 a share.
Extension and off-drug data from its SIGNAL-AA study could support monthly, every-two-months or quarterly maintenance dosing for bempikibart. Open-label-extension data are expected in the second half of 2027.
The company also added ADX-914-XL, a preclinical half-life-extended anti-IL-7Rα antibody designed for a longer dosing schedule than bempikibart, to its disclosed pipeline.
Q32 is evaluating bempikibart in broader alopecia populations and additional immunology-and-inflammation indications, expanding the stated development strategy beyond severe and very severe alopecia areata.